Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

209
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
209
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

699
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
699
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

395
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
395
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

166
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strong Maternal Health Curriculum Needed in Family Medicine.

American family physician·2024
Same author

Care of People Experiencing Homelessness.

American family physician·2022
Same author

Outpatient Burn Care: Prevention and Treatment.

American family physician·2020
Same author

Failure to thrive: an update.

American family physician·2011

Related Experiment Video

Updated: May 23, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

17.9K

Migraine Headache Prophylaxis.

Paige Moreland1, Brody Gaffney2, Jason S Lanham3

  • 1General Leonard Wood Army Community Hospital, Fort Leonard Wood, Missouri.

American Family Physician
|May 16, 2025
PubMed
Summary

Migraine prophylaxis aims to reduce headache frequency and severity. First-line treatments include medications like propranolol and topiramate, with OnabotulinumtoxinA effective for chronic migraine.

More Related Videos

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

658
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

7.7K

Related Experiment Videos

Last Updated: May 23, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

17.9K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

658
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

7.7K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine headaches affect 1% of the US population, causing significant disability.
  • Effective migraine prophylaxis is crucial for improving patient quality of life and reducing headache burden.

Purpose of the Study:

  • To review the goals, indications, and available treatment options for migraine prophylaxis.
  • To discuss first-line and second-line pharmacotherapies, as well as non-pharmacological interventions for migraine management.

Main Methods:

  • Literature review of current guidelines and evidence for migraine prophylaxis.
  • Analysis of first-line medications (e.g., propranolol, topiramate, CGRP antagonists), second-line options (e.g., amitriptyline), and OnabotulinumtoxinA.
  • Inclusion of non-pharmacological approaches like cognitive behavioral therapy and alternative agents.

Main Results:

  • First-line pharmacotherapies include beta-blockers, anticonvulsants, and CGRP antagonists, though cost can be a barrier for the latter.
  • OnabotulinumtoxinA is effective for chronic migraine, well-tolerated, and has low discontinuation rates.
  • Non-pharmacological options and alternative agents like magnesium and melatonin offer additional therapeutic strategies.

Conclusions:

  • Migraine prophylaxis involves a multi-faceted approach, including trigger management and various treatment modalities.
  • Treatment selection should consider efficacy, adverse events, cost, and patient preference for optimal outcomes.